Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 2.1% – Here’s Why

Shares of Actuate Therapeutics (NASDAQ:ACTU) fell 2.1% during mid-day trading on Tuesday . The stock traded as low as $7.85 and last traded at $8.11. 42,680 shares were traded during trading, an increase of 5% from the average session volume of 40,795 shares. The stock had previously closed at $8.28.

Actuate Therapeutics Stock Down 2.1 %

The firm has a 50 day simple moving average of $8.37.

Institutional Investors Weigh In On Actuate Therapeutics

A hedge fund recently bought a new stake in Actuate Therapeutics stock. KG&L Capital Management LLC bought a new position in Actuate Therapeutics (NASDAQ:ACTU) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 12,000 shares of the company’s stock, valued at approximately $89,000. KG&L Capital Management LLC owned approximately 0.06% of Actuate Therapeutics at the end of the most recent reporting period.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.